EULAR 2025 – SpA Panel Discussion Leading rheumatology experts discuss the latest research, treatment advances, and

Tweet Author

Tweet Content

EULAR 2025 – SpA Panel Discussion Leading rheumatology experts discuss the latest research, treatment advances, and clinical insights in axial spondyloarthritis. Hear what’s new from EULAR 2025 and what it means for improving patient outcomes. https://t.co/AcwtseWBi0 https://t.co/MzEN0VtLx6

Links

EULAR 2025 – SpA Panel Discussion | RheumNow https://buff.ly/vIf5heY

UK study of 17472 newly Dx #RA pts (10997 MTX, 4,540 csDMARDs; 13680 steroids-CS) w/ 1307 Serious Infx (SI) (3/100PY) &

Tweet Author

RheumNow

Tweet Content

UK study of 17472 newly Dx #RA pts (10997 MTX, 4,540 csDMARDs; 13680 steroids-CS) w/ 1307 Serious Infx (SI) (3/100PY) & 311 SI deaths. MTX signif decr. SI (adj HR 0.72) & CS no effect HR 0.99. SI assoc w/ age, smoker, comorbidity, seropositive, high DAS28. 1 DAS unit incr SI https://t.co/Zmsuaf7Rw3

What would it take for JAKs to ROCK the boat? JAK inhibitors have taken a beating over the last three years. The excit

Tweet Author

RheumNow

Tweet Content

What would it take for JAKs to ROCK the boat? JAK inhibitors have taken a beating over the last three years. The excitement and potential has been tempered by mounting cardiovascular safety concerns, but specifically in at-risk patients, compared to TNF inhibitors. Once the https://t.co/JgmfxGa6TY

24 June 2025

Remission in Axial Spondyloarthritis Unrelated to Gut Inflammation

Most patients with early, active axial spondyloarthritis (axSpA) who quickly received a tumor necrosis factor (TNF) inhibitor experienced remission, and it didn't matter whether or not they had intestinal inflammation at baseline, a small single-arm study found.

EMA has published a concept paper about the need for guidance to inform the development of systemic sclerosis (SSc) tre

Tweet Author

RheumNow

Tweet Content

EMA has published a concept paper about the need for guidance to inform the development of systemic sclerosis (SSc) treatments. They have identified study designs & endpoints; exploratory and confirmatory trials, and assessments of safety and efficacy. See draft here: https://t.co/WADBrw2uXe

SCLERODERMA Pt education page from JAMA Dermatology https://t.co/hILqCeUnE2 https://t.co/cZCgoRHbDZ

Tweet Author

RheumNow

Tweet Content

SCLERODERMA Pt education page from JAMA Dermatology https://t.co/hILqCeUnE2 https://t.co/cZCgoRHbDZ

Links

What Is Scleroderma? https://buff.ly/8PqSNNM

Persistent Burden in Early RA Despite Disease Control: insights from CareRA Trials Advances in the treatment of rheuma

Tweet Author

RheumNow

Tweet Content

Persistent Burden in Early RA Despite Disease Control: insights from CareRA Trials Advances in the treatment of rheumatoid arthritis (RA), particularly the treat-to-target strategy and the introduction of effective disease-modifying antirheumatic drugs (DMARDs), have improved https://t.co/cMiF6POKGS

Global burden of dz study - UN statistics show post-Menopausal women (PMW) are 20% of all women in 2021 (vs 13.7% 1990).

Tweet Author

RheumNow

Tweet Content

Global burden of dz study - UN statistics show post-Menopausal women (PMW) are 20% of all women in 2021 (vs 13.7% 1990). From 1990 to 2021, the prevalence of MSK Dz in PMW significantly risen, especially for RA, OA, and gout. https://t.co/HdkopkxLdv https://t.co/wsGhg0P1tL

Links

Global burden and trends of musculoskeletal disorders in postmenopausal elderly… https://buff.ly/xfpWpGI

A new mechanism of action in SARD-ILD Nerandomilast, an inhibitor of phosphodiesterase 4B, orally administered, is a n

Tweet Author

RheumNow

Tweet Content

A new mechanism of action in SARD-ILD Nerandomilast, an inhibitor of phosphodiesterase 4B, orally administered, is a new mechanism of action to treat lung fibrotic diseases. FIBRONEER-ILD, the Phase 3 RCT of Nerandomilast in patients with progressive pulmonary fibrosis, was https://t.co/goikCwJa2x

Survey of 154 Saudi established #RA pts on MTX >3mos; 64% claiming #MTX intolerance & 36% w/ MTX Intolerance Seve

Tweet Author

RheumNow

Tweet Content

Survey of 154 Saudi established #RA pts on MTX >3mos; 64% claiming #MTX intolerance & 36% w/ MTX Intolerance Severity Score (MISS) >6. But MTX intolerance was NOT related to dose or route of administration, meal or time of day. These were not new MTX starters https://t.co/6KWGcZvx4o

Topics

EULAR 2025 – SpA Panel Discussion Leading rheumatology experts discuss the latest research, treatment advances, and

UK study of 17472 newly Dx #RA pts (10997 MTX, 4,540 csDMARDs; 13680 steroids-CS) w/ 1307 Serious Infx (SI) (3/100PY) &

What would it take for JAKs to ROCK the boat? JAK inhibitors have taken a beating over the last three years. The excit

EMA has published a concept paper about the need for guidance to inform the development of systemic sclerosis (SSc) tre

SCLERODERMA Pt education page from JAMA Dermatology https://t.co/hILqCeUnE2 https://t.co/cZCgoRHbDZ

Persistent Burden in Early RA Despite Disease Control: insights from CareRA Trials Advances in the treatment of rheuma

Global burden of dz study - UN statistics show post-Menopausal women (PMW) are 20% of all women in 2021 (vs 13.7% 1990).

A new mechanism of action in SARD-ILD Nerandomilast, an inhibitor of phosphodiesterase 4B, orally administered, is a n

Survey of 154 Saudi established #RA pts on MTX >3mos; 64% claiming #MTX intolerance & 36% w/ MTX Intolerance Seve

Do you get our email newsletter?